These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
192 related articles for article (PubMed ID: 25135281)
21. Autophagy and oxidative stress in gliomas with IDH1 mutations. Gilbert MR; Liu Y; Neltner J; Pu H; Morris A; Sunkara M; Pittman T; Kyprianou N; Horbinski C Acta Neuropathol; 2014 Feb; 127(2):221-33. PubMed ID: 24150401 [TBL] [Abstract][Full Text] [Related]
22. Identification of MGMT promoter methylation sites correlating with gene expression and IDH1 mutation in gliomas. Zhang J; Yang JH; Quan J; Kang X; Wang HJ; Dai PG Tumour Biol; 2016 Oct; 37(10):13571-13579. PubMed ID: 27468718 [TBL] [Abstract][Full Text] [Related]
23. Single-nucleus transcriptomics of IDH1- and TP53-mutant glioma stem cells displays diversified commitment on invasive cancer progenitors. Gulaia V; Shmelev M; Romanishin A; Shved N; Farniev V; Goncharov N; Biktimirov A; Vargas IL; Khodosevich K; Kagansky A; Kumeiko V Sci Rep; 2022 Nov; 12(1):18975. PubMed ID: 36348001 [TBL] [Abstract][Full Text] [Related]
24. Glioma stem cells are more aggressive in recurrent tumors with malignant progression than in the primary tumor, and both can be maintained long-term in vitro. Huang Q; Zhang QB; Dong J; Wu YY; Shen YT; Zhao YD; Zhu YD; Diao Y; Wang AD; Lan Q BMC Cancer; 2008 Oct; 8():304. PubMed ID: 18940013 [TBL] [Abstract][Full Text] [Related]
25. Mutant IDH1 expression is associated with down-regulation of monocarboxylate transporters. Viswanath P; Najac C; Izquierdo-Garcia JL; Pankov A; Hong C; Eriksson P; Costello JF; Pieper RO; Ronen SM Oncotarget; 2016 Jun; 7(23):34942-55. PubMed ID: 27144334 [TBL] [Abstract][Full Text] [Related]
26. PRMT1 driven PTX3 regulates ferritinophagy in glioma. Lathoria K; Gowda P; Umdor SB; Patrick S; Suri V; Sen E Autophagy; 2023 Jul; 19(7):1997-2014. PubMed ID: 36647288 [TBL] [Abstract][Full Text] [Related]
27. cMYC expression in infiltrating gliomas: associations with IDH1 mutations, clinicopathologic features and outcome. Odia Y; Orr BA; Bell WR; Eberhart CG; Rodriguez FJ J Neurooncol; 2013 Nov; 115(2):249-59. PubMed ID: 23934175 [TBL] [Abstract][Full Text] [Related]
28. Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. Sanson M; Marie Y; Paris S; Idbaih A; Laffaire J; Ducray F; El Hallani S; Boisselier B; Mokhtari K; Hoang-Xuan K; Delattre JY J Clin Oncol; 2009 Sep; 27(25):4150-4. PubMed ID: 19636000 [TBL] [Abstract][Full Text] [Related]
30. Enrichment of branched chain amino acid transaminase 1 correlates with multiple biological processes and contributes to poor survival of IDH1 wild-type gliomas. Yi L; Fan X; Li J; Yuan F; Zhao J; Nistér M; Yang X Aging (Albany NY); 2021 Jan; 13(3):3645-3660. PubMed ID: 33493139 [TBL] [Abstract][Full Text] [Related]
31. IDH mutant gliomas escape natural killer cell immune surveillance by downregulation of NKG2D ligand expression. Zhang X; Rao A; Sette P; Deibert C; Pomerantz A; Kim WJ; Kohanbash G; Chang Y; Park Y; Engh J; Choi J; Chan T; Okada H; Lotze M; Grandi P; Amankulor N Neuro Oncol; 2016 Oct; 18(10):1402-12. PubMed ID: 27116977 [TBL] [Abstract][Full Text] [Related]
32. RARRES2 is Downregulated in Isocitrate Dehydrogenase 1 Mutant Glioma Patients and Served as an Unfavorable Prognostic Factor of Glioma. Wang H; Wang X; Xu L; Zhang J World Neurosurg; 2023 Aug; 176():e610-e622. PubMed ID: 37271257 [TBL] [Abstract][Full Text] [Related]
33. CRISPR Editing of Mutant IDH1 R132H Induces a CpG Methylation-Low State in Patient-Derived Glioma Models of G-CIMP. Moure CJ; Diplas BH; Chen LH; Yang R; Pirozzi CJ; Wang Z; Spasojevic I; Waitkus MS; He Y; Yan H Mol Cancer Res; 2019 Oct; 17(10):2042-2050. PubMed ID: 31292202 [TBL] [Abstract][Full Text] [Related]
34. Non-invasive detection of 2-hydroxyglutarate and other metabolites in IDH1 mutant glioma patients using magnetic resonance spectroscopy. Pope WB; Prins RM; Albert Thomas M; Nagarajan R; Yen KE; Bittinger MA; Salamon N; Chou AP; Yong WH; Soto H; Wilson N; Driggers E; Jang HG; Su SM; Schenkein DP; Lai A; Cloughesy TF; Kornblum HI; Wu H; Fantin VR; Liau LM J Neurooncol; 2012 Mar; 107(1):197-205. PubMed ID: 22015945 [TBL] [Abstract][Full Text] [Related]
35. SPINT2 is hypermethylated in both IDH1 mutated and wild-type glioblastomas, and exerts tumor suppression via reduction of c-Met activation. Liu F; Cox CD; Chowdhury R; Dovek L; Nguyen H; Li T; Li S; Ozer B; Chou A; Nguyen N; Wei B; Antonios J; Soto H; Kornblum H; Liau L; Prins R; Nghiemphu PL; Yong W; Cloughesy T; Lai A J Neurooncol; 2019 May; 142(3):423-434. PubMed ID: 30838489 [TBL] [Abstract][Full Text] [Related]
36. D-2-Hydroxyglutarate producing neo-enzymatic activity inversely correlates with frequency of the type of isocitrate dehydrogenase 1 mutations found in glioma. Pusch S; Schweizer L; Beck AC; Lehmler JM; Weissert S; Balss J; Miller AK; von Deimling A Acta Neuropathol Commun; 2014 Feb; 2():19. PubMed ID: 24529257 [TBL] [Abstract][Full Text] [Related]
37. The R132H mutation in IDH1 promotes the recruitment of NK cells through CX3CL1/CX3CR1 chemotaxis and is correlated with a better prognosis in gliomas. Ren F; Zhao Q; Huang L; Zheng Y; Li L; He Q; Zhang C; Li F; Maimela NR; Sun Z; Jia Q; Ping Y; Zhang Z; Chen X; Yue Y; Liu S; Cao L; Zhang Y Immunol Cell Biol; 2019 May; 97(5):457-469. PubMed ID: 30575118 [TBL] [Abstract][Full Text] [Related]
38. Hominoid-specific enzyme GLUD2 promotes growth of IDH1R132H glioma. Chen R; Nishimura MC; Kharbanda S; Peale F; Deng Y; Daemen A; Forrest WF; Kwong M; Hedehus M; Hatzivassiliou G; Friedman LS; Phillips HS Proc Natl Acad Sci U S A; 2014 Sep; 111(39):14217-22. PubMed ID: 25225364 [TBL] [Abstract][Full Text] [Related]
39. Methylation dependent down-regulation of G0S2 leads to suppression of invasion and improved prognosis of IDH1-mutant glioma. Fukunaga T; Fujita Y; Kishima H; Yamashita T PLoS One; 2018; 13(11):e0206552. PubMed ID: 30388142 [TBL] [Abstract][Full Text] [Related]
40. Identification of Hedgehog pathway responsive glioblastomas by isocitrate dehydrogenase mutation. Gerardo Valadez J; Grover VK; Carter MD; Calcutt MW; Abiria SA; Lundberg CJ; Williams TV; Cooper MK Cancer Lett; 2013 Jan; 328(2):297-306. PubMed ID: 23063752 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]